#United States #New York #Pomerantz Law #REGENXBIO #RGNX

Investigation into REGENXBIO Inc. by Pomerantz Law Firm

The Pomerantz Law Firm has initiated an investigation concerning allegations of securities fraud on behalf of investors in REGENXBIO Inc. (NASDAQ: RGNX). This inquiry seeks to determine whether the company and certain officers and directors might have engaged in improper business practices detrimental to shareholders.

Background Information

On January 28, 2026, REGENXBIO announced that the U.S. Food and Drug Administration (FDA) imposed a clinical hold on the company's investigational gene therapy, RGX-111. This therapy is aimed at treating MPS I, or Hurler syndrome, but was halted after initial evaluations of a case where a participant developed a neoplasm in the CNS during the Phase I/II study.

Simultaneously, the FDA also placed RGX-121, intended for MPS II or Hunter Syndrome, under clinical hold, citing shared characteristics and risks between the two therapies' clinical studies. Subsequently, REGENXBIO's stock price plummeted by $2.40, translating to a 17.9% decrease, closing at $11.01 the same day.

Investor Impact and Class Action

Given the drastic fall in stock price and the circumstances surrounding the FDA’s decision, investors who experienced losses are urged to come forward. Pomerantz Law Firm is particularly keen on hearing from those affected by this news – a chance to hold the company accountable for any potential misconduct.

As a reputable entity in the field of securities litigation, Pomerantz has a rich history of representing victims of corporate fraud and misconduct. The firm was founded by Abraham L. Pomerantz, viewed as a pioneer in securities class actions, and has recovered significant damages for class members over its 85-year history.

Potential plaintiffs should reach out to Danielle Peyton at Pomerantz by emailing [email protected] or calling 646-581-9980, extension 7980, to get involved or to obtain further information about class action opportunities.

Conclusion

The investigation by Pomerantz marks a significant moment for investors of REGENXBIO Inc. Those impacted by the recent developments have the opportunity to engage in legal recourse. The outcome of such actions could not only impact the company's managerial practices but also provide a path for recovery for those who suffered financial losses due to the alleged securities fraud. Staying informed and actively participating in these developments can be vital for affected investors.